# The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With Rifaximin

> **NCT06223685** · NA · COMPLETED · sponsor: **Pomeranian Medical University Szczecin** · enrollment: 129 (actual)

## Conditions studied

- Irritable Bowel Syndrome
- Small Intestinal Bacterial Overgrowth
- SIBO

## Interventions

- **DRUG:** Rifaximin (Xifaxan) 1200mg/day
- **DIETARY_SUPPLEMENT:** Probiotic
- **DRUG:** XIFAXAN® (Rifaximin) 1600mg/day

## Key facts

- **NCT ID:** NCT06223685
- **Lead sponsor:** Pomeranian Medical University Szczecin
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2025-08-30
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06223685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06223685, "The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With Rifaximin". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06223685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*